| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CeriBell, Inc.$19.56
-0.08 (-0.41%)
F 17Pipeline Score MedTech · Commercial
Market Cap
712.18 M
EPS
-1.63
P/E Ratio
-
Value Trade
6.00 M
SEC Financials
Q1 2026Dilution Risk
Revenue
26.49 M
R&D Expenses
6.16 M
Operating CF
-19.30 M
Total Assets
178.08 M
Total Liabilities
37.27 M
Equity
140.81 M
D/E Ratio
12,345
14.45 %
Week
-11.42 %
1 Month
-7.08 %
3 Month
37.31 %
6 Month
-19.3 %
5 Year
-19.3 %
All Time
Cash Data
Cash Position
141.18 M
Monthly Burn
6.43 M
Runway
20.2 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
197.19 K
52 Week Range
10.85 - 24.33
% held by Insiders
34.88 %
% held by Institutions
66.23 %
Enterprise Value
593.12 M
Total Shares
37.11 M
Short %
9.15 %
Float Shares
21.60 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 16%
Micro Cap (rank 766 of 911)
Percentile RankCeriBell, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CBLL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CBLL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CBLLCeribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Ceribell announced the publication of a study in Critical Care Medicine demonstrating that its Clarity AI algorithm for measuring seizure burden correlates with neurological outcomes at discharge. The research involved 359 patients and highlighted that higher seizure burdens are linked to increased risks of severe disability and death. This advancement supports the need for real-time monitoring in critical care settings.
Read more →CBLL▲ +6.7%on this news
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
Ceribell, Inc. announced that its CEO, Dr. Jane Chao, will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The event will showcase Ceribell's innovative approach to diagnosing and managing serious neurological conditions through its FDA-cleared Ceribell System. A webcast of the presentation will be available on the company's website.
Read more →CBLLCeribell Reports First Quarter 2026 Financial Results
Ceribell, Inc. reported a strong financial performance for Q1 2026, with total revenue reaching $26.5 million, a 29% increase compared to the same quarter in 2025. The company also launched new neonate and pediatric products and received a proposed rule for reimbursement from CMS. However, operating expenses rose significantly, leading to a net loss of $19.7 million.
Read more →CBLL▼ -7.5%on this news
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell, Inc. will participate in the Bank of America Securities 2026 Health Care Conference, featuring CEO Jane Chao and CFO Scott Blumberg in a fireside chat. The event is scheduled for May 13, 2026. Ceribell specializes in advanced diagnostic solutions for neurological conditions, with its FDA-cleared Ceribell System designed for acute-care settings.
Read more →CBLLCeribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. announced it will release its first quarter 2026 financial results on May 11, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. The Ceribell System, which aids in diagnosing neurological conditions, is FDA-cleared for use in critical care settings.
Read more →CBLLCeribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell, Inc. reported strong financial results for Q4 and full year 2025, with total revenue reaching $89.1 million, a 36% increase from 2024. The company expanded its seizure detection algorithm to include pediatric patients and anticipates continued growth in 2026. However, operating expenses rose significantly, contributing to a larger net loss compared to the previous year.
Read more →CBLLCeribell to Participate in Upcoming March Investor Conferences
Ceribell, Inc. has announced its participation in two upcoming investor conferences, enhancing its visibility within the industry. CFO Scott Blumberg will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, and both Scott Blumberg and CEO Jane Chao will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3. The company focuses on innovative solutions for diagnosing and managing serious neurological conditions, emphasizing the capabilities of its FDA-cleared Ceribell System.
Read more →CBLLCeribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Ceribell, Inc. will announce its fourth quarter and full year 2025 financial results on February 24, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. Ceribell specializes in medical technology for neurological conditions, with its FDA-cleared EEG system designed for rapid diagnosis and monitoring.
Read more →CBLLCeribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell, Inc. has been granted FDA Breakthrough Device Designation for its innovative Large Vessel Occlusion (LVO) stroke detection monitor. This device utilizes AI algorithms to analyze EEG signals, enabling early detection of LVO strokes in hospital settings. The designation underscores Ceribell's commitment to improving neurological care and addresses the critical need for timely stroke detection.
Read more →CBLL30/2025 Rebecca Robertson Board Chair Ceribell 360 N Pastoria Avenue Sunnyvale, CA 94085, USA Subject: Resignation from the Board of Directors Dear Rebecca Robertson and Members of the Board, Please accept this letter as
Lucian Iancovici, M.D., has announced his resignation from the Board of Directors at Ceribell, effective December 31, 2025. His decision is not due to any disagreements with the company's leadership or policies, but rather a personal choice to pursue other ventures. Dr. Iancovici expressed pride in the board's accomplishments during his tenure and committed to a smooth transition process. He has no outstanding claims against the company and will maintain confidentiality regarding sensitive information.
Read more →CBLLCeribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. (Nasdaq: CBLL) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, led by CEO Jane Chao, Ph.D. The presentation will highlight the company's focus on improving diagnosis and management for patients with serious neurological conditions. The Ceribell System, a point-of-care EEG platform, has received FDA clearance and is designed for use in intensive care units and emergency rooms. The conference will feature a live and archived webcast accessible on the Ceribell website.
Read more →CBLLCeribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to addr
Ceribell, Inc. has received FDA 510(k) clearance for its innovative delirium monitoring solution, a first-of-its-kind device aimed at addressing the needs of critically ill patients. This AI-powered electroencephalography system enhances delirium detection and monitoring alongside seizure management. The solution is supported by extensive validation and aims to reduce healthcare burdens associated with delirium. Ceribell plans to finalize its go-to-market strategy to implement this technology effectively in clinical settings.
Read more →CBLLCeribell Receives FDA 510(k) Clearance for Use of Clarity Ⓡ Algorithm for Neonates Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside det
Ceribell has announced that it has received FDA 510(k) clearance for its Clarity algorithm, designed to detect seizures in neonates and patients of all ages. This represents a significant advancement in neonatal care, as the Clarity algorithm is the only FDA-cleared technology for electrographic seizure detection from pre-term infants to adults. The system allows for rapid bedside monitoring and diagnosis, which can significantly improve outcomes for newborns who may experience seizures. A validation dataset comprising EEG data from over 700 patients supports the effectiveness of this technology.
Read more →CBLLCeribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
Ceribell, Inc. (CBLL) announced its participation in the Piper Sandler 37th Annual Healthcare Conference, with CEO Jane Chao set to present on December 3, 2025. This event highlights Ceribell's focus on transforming the diagnosis and management of serious neurological conditions. The company has developed an advanced electroencephalography platform designed for acute care settings. A live webcast of the presentation will be available on Ceribell's investor relations website.
Read more →CBLLCeribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Ceribell, Inc. announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. The event will be held in New York and will also feature a live and archived webcast. Ceribell specializes in advanced diagnostic solutions for neurological conditions.
Read more →CBLL▲ +7.9%on this newsshared move
Ceribell Reports Third Quarter 2025 Financial Results
Ceribell, Inc. reported a strong third quarter for 2025, with total revenue reaching $22.6 million, a 31% increase from the previous year. The company is optimistic about its future, raising its revenue guidance for the full year to between $87 million and $89 million. However, it also reported a net loss of $13.5 million, reflecting increased operating expenses due to investments in growth.
Read more →CBLL▲ +7%on this news
Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
Ceribell, Inc. announced that it will report its financial results for Q3 2025 on November 4, 2025. The company will host a conference call to discuss these results, available to investors via a dedicated phone line and webcast. Ceribell is dedicated to improving the diagnosis and management of serious neurological conditions with their innovative EEG platform, which has received FDA clearance.
Read more →CBLLMedtech Leader Erica Rogers Joins Ceribell Board of Directors
Ceribell, Inc. has appointed Erica Rogers to its Board of Directors, bringing over 30 years of experience in the medical device industry. Rogers, a former CEO of Silk Road Medical, is expected to aid Ceribell in expanding access to its point-of-care EEG system. This technology aims to enhance timely care for critically ill patients across the U.S.
Read more →CBLLCeribell Reports Second Quarter 2025 Financial Results
Ceribell, Inc. reported its financial results for the second quarter of 2025, highlighting a significant revenue increase of 38% year-over-year to $21.2 million. The company achieved a gross margin of 88%, reflecting its operational efficiency. However, the operating expenses rose sharply by 56%, resulting in a net loss of $13.6 million. Ceribell has raised its full-year revenue guidance, projecting growth of approximately 30% to 34% over the previous year, indicating a positive outlook despite financial losses.
Read more →CBLLCeribell to Participate in the Canaccord Genuity 45th Annual Growth Conference
Ceribell, Inc. announced its participation in the Canaccord Genuity 45th Annual Growth Conference, where CEO Jane Chao will present. The event is scheduled for August 12, 2025, and will be accessible via a live and archived webcast. Ceribell focuses on innovative solutions for neurological conditions, with its FDA-cleared EEG platform already in use in critical care settings.
Read more →CBLLCeribell to Report Second Quarter 2025 Financial Results on August 5, 2025
Ceribell, Inc. has announced that it will release its financial results for the second quarter of 2025 on August 5, 2025. A conference call will follow the release, allowing management to discuss the results with investors. The company specializes in medical technology for neurological conditions and has developed an FDA-cleared EEG platform.
Read more →CBLLCeribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Ceribell, Inc. has filed complaints against Natus Medical for patent infringement and unfair competition, seeking an investigation by the U.S. International Trade Commission and filing a lawsuit in Delaware. The complaints allege that Natus infringes on six patents related to Ceribell's EEG technology. Ceribell emphasizes its commitment to fair competition and protecting its innovations.
Read more →CBLLCeribell to Participate in the William Blair 45th Annual Growth Stock Conference
Ceribell, Inc. will present at the William Blair 45th Annual Growth Stock Conference on June 3, 2025. CEO Jane Chao will discuss the company's innovative EEG platform designed for acute care settings. The event highlights Ceribell's commitment to improving diagnosis and management of serious neurological conditions.
Read more →CBLL▲ +6.8%on this news
Ceribell Reports First Quarter 2025 Financial Results
Ceribell, Inc. reported its first-quarter financial results for 2025, showcasing a 42% increase in total revenue to $20.5 million compared to the same quarter in 2024. The company achieved a gross margin of 88%, benefiting from expanded adoption of its medical technology for diagnosing neurological conditions. However, operating expenses rose significantly, leading to a net loss of $12.8 million. Looking forward, Ceribell has raised its full-year revenue guidance, anticipating growth of approximately 27% to 33% compared to the previous year.
Read more →CBLLCeribell to Participate in the Bank of America Securities 2025 Health Care Conference
Ceribell, Inc. will participate in the upcoming Bank of America Securities 2025 Health Care Conference, with CEO Jane Chao scheduled to present on May 14, 2025. The presentation aims to showcase Ceribell's advancements in medical technology, specifically its novel EEG platform for diagnosing neurological conditions. The company is focused on revolutionizing patient care with its proprietary system, which is already FDA cleared and utilized in critical care settings.
Read more →CBLLCeribell Receives FedRAMP High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
Ceribell has received FedRAMP High authorization, enabling its AI-powered point-of-care EEG system to be adopted across federal healthcare facilities, including those in the U.S. Department of Veterans Affairs. This authorization is significant as it positions Ceribell among a select group of companies that meet the government’s stringent cybersecurity standards. The implementation of this technology is expected to improve the speed of diagnoses and treatment for patients at risk of non-convulsive seizures, particularly benefiting U.S. veterans. The achievement also underscores Ceribell's commitment to securing patient data and meeting high regulatory standards.
Read more →CBLLCeribell to Report First Quarter 2025 Financial Results on May 8, 2025
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its financial results for the first quarter of 2025 after market close on May 8, 2025. The company will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Ceribell specializes in medical technology aimed at transforming diagnosis and management for patients with serious neurological conditions.
Read more →CBLLCeribell Reports Fourth Quarter and Full Year 2024 Financial Results Sunnyvale, Calif. –
Ceribell, Inc. has announced its fourth quarter and full year financial results for 2024, showcasing significant growth in revenue and patient treatment. The company reported total revenue of $18.5 million for Q4 2024, a 41% increase from the previous year, and a yearly total of $65.4 million, reflecting a 45% year-over-year growth. Despite this growth, Ceribell reported a net loss of $12.6 million for the fourth quarter. Looking ahead, Ceribell projects revenue growth of approximately 24% to 30% for 2025.
Read more →CBLLCeribell to Participate in the 45th Annual TD Cowen Healthcare Conference
Ceribell, Inc. announced its participation in the 45th Annual TD Cowen Healthcare Conference, scheduled for March 3, 2025. The company's CEO and CFO will engage in a fireside chat at the event, enhancing its visibility in the medical technology sector. Ceribell focuses on the diagnosis and management of serious neurological conditions with its innovative EEG platform. A live webcast of the presentation will be accessible on the company's investor relations website.
Read more →CBLLCeribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Ceribell, Inc. has announced the date for its financial results for the fourth quarter and full year of 2024, scheduled for February 25, 2025. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Ceribell is recognized for its advanced EEG platform that addresses critical needs in acute care for neurological conditions.
Read more →CBLLCorporate Presentation January 2025 Forward Looking Statement This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about the Company and its i
Ceribell's corporate presentation highlights the company's focus on an AI-powered EEG platform aimed at optimizing care for critically ill patients with neurological conditions. As of September 2024, the company reported a revenue growth of 46% year-over-year and has identified a substantial $2 billion U.S. annual addressable market. However, the presentation also emphasizes significant risks, including uncertainties regarding their forward-looking statements and operational challenges in a competitive environment.
Read more →CBLLCeribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. announced that CEO Jane Chao will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company aims to enhance the diagnosis and management of serious neurological conditions with its innovative Ceribell System. This point-of-care EEG platform has received FDA clearance and is already in use in various acute care settings across the U.S. The presentation will be accessible via a live webcast on Ceribell's website.
Read more →CBLLCeribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing
Ceribell, Inc. has appointed Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing. Rodenbush will lead the company's hiring and talent development efforts, while Price will focus on enhancing market development strategies. Both executives bring a wealth of experience from their previous roles in their respective fields. Ceribell aims to leverage their expertise to expand its presence and improve healthcare solutions for patients with serious neurological conditions.
Read more →CBLLCeribell Reports Third Quarter 2024 Financial Results Sunnyvale, CA –
Ceribell, Inc. reported its financial results for the third quarter of 2024, showcasing significant growth with total revenue of $17.2 million, a 48% increase compared to the same quarter last year. The company achieved a strong gross margin of 87% and concluded its initial public offering, obtaining approximately $188 million in net proceeds. However, operating expenses also rose sharply, leading to a net loss of $10.4 million for the quarter. Looking ahead, Ceribell expects 2024 revenue to grow between 42% and 43% compared to the previous year.
Read more →CBLLCeribell Receives Authority to Operate from the U.S. Department of Veterans Affairs
Ceribell, Inc. has received an Authority to Operate from the U.S. Department of Veterans Affairs, enabling the full deployment of its point-of-care EEG technology across VA hospitals. This significant milestone allows for the integration of Ceribell's technology into VA systems, facilitating better neurological emergency management and improving patient outcomes. The system is particularly beneficial for military veterans, who are at higher risk for seizure disorders. The VA's National Tele-EEG program will assist in implementing this technology nationwide, aiming for more efficient and effective neurological care.
Read more →CBLLCeribell to Report Third Quarter 2024 Financial Results on November 12, 2024 Ceribell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of...
Ceribell, Inc. will announce its third quarter 2024 financial results on November 12, 2024. Following the release, management will host a conference call at 1:30 p.m. PT to discuss the results. Investors can participate by calling designated numbers or accessing a webcast on the company's website.
Read more →CBLLNew Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG Ceribell, Inc. (Nasdaq: CBLL), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with...
Ceribell, Inc. presented five abstracts at the 2024 Neurocritical Care Society Annual Meeting, showcasing the benefits of its point-of-care EEG system and AI-powered Clarity algorithm. The studies indicate that using Ceribell can lead to shorter hospital stays and improved functional outcomes for patients at risk of seizures. The research emphasizes the importance of early detection and intervention in critical care settings.
Read more →CBLLCeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of...
CeriBell, Inc. has successfully closed its upsized initial public offering, selling 12,196,969 shares at $17.00 each, totaling around $207.3 million in gross proceeds. The offering included additional shares purchased by underwriters, enhancing the company's financial position. CeriBell's stock began trading on the Nasdaq Global Select Market on October 11, 2024.
Read more →CBLLCeriBell, Inc. Announces Pricing of Upsized Initial Public Offering CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of...
CeriBell, Inc. has announced the pricing of its upsized initial public offering, offering 10,606,060 shares at $17.00 each. The IPO is expected to raise around $180.3 million, with trading set to commence on October 11, 2024. The company has granted underwriters a 30-day option to purchase additional shares.
Read more →CBLLCeribell Announces Publication of Study Demonstrating Significant Reduction in Length of ICU Stays and Better Patient Outcomes with Ceribell Point-of-Care EEG Compared to Conventional EEG Ceribell, Inc., a commercial-stage medical technology company focused on transforming the detection and management of patients with serious...
Ceribell, Inc. announced a study showing that its point-of-care EEG significantly reduces ICU stays by an average of 4.1 days and decreases the rate of patients leaving with disabilities. The study, published in Neurocritical Care, highlights the faster EEG acquisition time and better patient outcomes compared to conventional EEG methods. These findings underscore the importance of early assessment using Ceribell's technology in acute care settings.
Read more →CBLLCeribell Appoints Sean Manni as Senior Vice President of Sales Today, Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG diagnostic system, announced the appointment of Sean Manni as Senior...
Ceribell, Inc. has appointed Sean Manni as Senior Vice President of Sales to lead its commercial sales organization. Manni, a healthcare sales veteran with over 25 years of experience, is expected to drive the company's growth and expand its market presence in the U.S. His previous success at Omnicell highlights his capability in transforming sales strategies and achieving significant revenue growth.
Read more →CBLLCeribell to Present at the 42nd Annual J.P. Morgan Healthcare Conference Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG system, announced today that Jane Chao, Ph.D., CEO and Co-founder, will...
Ceribell, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Jane Chao will discuss the company's innovative AI-powered EEG system, which is FDA-approved for diagnosing electrographic status epilepticus. The technology aims to enhance the efficiency and accessibility of EEG diagnostics in acute care settings.
Read more →CBLLCeribell Launches ClarityPro™ AI, Expanding Access to Critical Diagnosis of Electrographic Status Epilepticus Ceribell, Inc.® today announced the commercial release of its new AI algorithm, ClarityPro™, accompanying the availability of potential additional...
Ceribell, Inc. has launched ClarityPro™, an AI algorithm designed to diagnose electrographic status epilepticus (ESE) in critically ill patients. This device is the first of its kind to receive FDA approval for stand-alone diagnosis and offers hospitals potential reimbursement for its use. ClarityPro™ enhances patient monitoring and treatment efficiency, aiming to improve outcomes for patients experiencing seizures.
Read more →CBLLCeribell Appoints Joshua Copp as Chief Operating Officer Today, Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG diagnostic system, announced the appointment of Joshua Copp as Chief...
Ceribell, Inc. has appointed Joshua Copp as Chief Operating Officer to enhance its operations and strategic guidance. With a strong background from McKinsey & Co., Copp aims to help Ceribell scale its AI-powered EEG diagnostic system. His expertise is expected to contribute significantly to the company's mission in seizure management.
Read more →CBLLCeribell Appoints Louisa Daniels as General Counsel Ceribell, Inc.®, the pioneer in AI-powered point-of-care neurodiagnostics, today announced Louisa Daniels has joined the medical device company as...
Ceribell, Inc. has appointed Louisa Daniels as General Counsel, bringing extensive legal expertise from her previous roles at Pfizer and Recursion Pharmaceuticals. Her appointment is expected to support Ceribell's growth as it aims to enhance the availability of point-of-care EEG diagnostics. Daniels expressed pride in joining a company that is innovating in the field of neurological care.
Read more →CBLLCeribell Receives FDA 510(k) Clearance and CMS NTAP Reimbursement for New ClarityPro™ Software with Electrographic Status Epilepticus Diagnostic Indication Ceribell, Inc.® today announced that its new software ClarityPro has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
Ceribell, Inc. has announced that its ClarityPro software has received FDA 510(k) clearance for diagnosing Electrographic Status Epilepticus (ESE). This follows the software's Breakthrough Device Designation by the FDA. Additionally, the U.S. Centers for Medicare and Medicaid Services (CMS) has granted NTAP reimbursement for ClarityPro, allowing for up to $913.90 per eligible Medicare patient case, effective October 1, 2023.
Read more →Competitive Position
How CBLL ranks across every disease it competes inCompetitive Position is a premium feature
See how CBLL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial